Fielmann Group AG is involved in purchase and sale of goods, in physical stores as well as wholesale and online, particularly in optometric and hearing acoustics sectors, and especially sales of all kinds of vision aids - particularly glasses, eyeewear frames and lenses, sunglasses, contact lenses, accessories, hearing systems as well as personal protective eqipments... Show more
FLMNF saw its Momentum Indicator move below the 0 level on July 29, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 12 similar instances where the indicator turned negative. In of the 12 cases, the stock moved further down in the following days. The odds of a decline are at .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.953) is normal, around the industry mean (10.661). P/E Ratio (27.336) is within average values for comparable stocks, (62.050). FLMNF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.847). Dividend Yield (0.022) settles around the average of (0.016) among similar stocks. P/S Ratio (1.908) is also within normal values, averaging (83.916).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. FLMNF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FLMNF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
Industry PharmaceuticalsOther
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
MFEM | 21.57 | 0.01 | +0.05% |
PIMCO RAFI Dyn Mlt-Fctr Emrg Mkts Eq ETF | |||
PHO | 71.49 | 0.01 | +0.01% |
Invesco Water Resources ETF | |||
RBLD | 73.32 | N/A | N/A |
First Trust Alerian US NextGen InfrasETF | |||
LDRH | 24.90 | -0.01 | -0.02% |
iShares iBonds 1-5 Year High Yield and Income Ladder ETF | |||
GQRE | 59.46 | -0.21 | -0.35% |
FlexShares Glbl Quality Real Estate ETF |
A.I.dvisor tells us that FLMNF and CNMD have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that FLMNF and CNMD's prices will move in lockstep.
Ticker / NAME | Correlation To FLMNF | 1D Price Change % | ||
---|---|---|---|---|
FLMNF | 100% | N/A | ||
CNMD - FLMNF | 23% Poorly correlated | +2.42% | ||
ESLOY - FLMNF | 2% Poorly correlated | +0.39% | ||
FZMD - FLMNF | 2% Poorly correlated | N/A | ||
EKTAY - FLMNF | 1% Poorly correlated | +1.03% | ||
FSPKF - FLMNF | 1% Poorly correlated | N/A | ||
More |
Ticker / NAME | Correlation To FLMNF | 1D Price Change % |
---|---|---|
FLMNF | 100% | N/A |
Pharmaceuticals category (394 stocks) | 2% Poorly correlated | +0.45% |
Pharmaceuticals: Other category (105 stocks) | 1% Poorly correlated | +0.07% |